Danaher (NYSE:DHR) 株価情報

Danaher

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Danaher Corp

DEUTSCHE EUROSHOP UNS/ADR by Deutsche Euroshop AG

Deutsche EuroShop AG

Whales with a lot of money to spend have taken a noticeably bearish stance on Danaher.
Looking at options history for Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) we detected 16 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 56% with bearish.
From the overall spotted trades, 14 are puts, for a total amount of $1,099,493 and 2, calls, for a total amount of $324,480.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $170.0 to $210.0 for Danaher over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Danaher's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Danaher's whale activity within a strike price range from $170.0 to $210.0 in the last 30 days. 
<h3>Danaher Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745604051_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/25/25</td>
<td>$27.2</td>
<td>$26.3</td>
<td>$27.04</td>
<td>$170.00</td>
<td>$246.0K</td>
<td align="right">127</td>
<td align="right">92</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$16.2</td>
<td>$16.2</td>
<td>$16.2</td>
<td>$210.00</td>
<td>$105.5K</td>
<td align="right">866</td>
<td align="right">418</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$17.7</td>
<td>$16.7</td>
<td>$17.23</td>
<td>$210.00</td>
<td>$103.2K</td>
<td align="right">866</td>
<td align="right">118</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$17.5</td>
<td>$15.8</td>
<td>$16.94</td>
<td>$210.00</td>
<td>$101.6K</td>
<td align="right">866</td>
<td align="right">241</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$16.5</td>
<td>$15.8</td>
<td>$15.7</td>
<td>$210.00</td>
<td>$97.3K</td>
<td align="right">866</td>
<td align="right">539</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
After a thorough review of the options trading surrounding Danaher, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Danaher's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,116,247, with DHR's price up by 0.15%, positioned at $196.79.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 88 days.</li>
</ul>
<h3>What Analysts Are Saying About Danaher</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $239.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from UBS persists with their Buy rating on Danaher, maintaining a target price of $240. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $250. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Danaher, which currently sits at a price target of $225. 
&#x2A; An analyst from Jefferies persists with their Buy rating on Danaher, maintaining a target price of $230. 
&#x2A; In a cautious move, an analyst from Guggenheim downgraded its rating to Buy, setting a price target of $250. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Danaher, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Market Whales and Their Recent Bets on DHR Options

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 3.44% on an annualized basis producing an average annual return of 13.45%. Currently, Danaher has a market capitalization of $140.63 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $351.30 today based on a price of $196.50 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745528418_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$100 Invested In Danaher 10 Years Ago Would Be Worth This Much Today

Danaher's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) short percent of float has fallen 22.13% since its last report. The company recently reported that it has 6.03 million shares sold short, which is 0.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Danaher Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745521224_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Danaher has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Danaher's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Danaher's peer group average for short interest as a percentage of float is 6.62%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Danaher?

Danaher Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) on Tuesday reported first-quarter 2025 sales of $5.74 billion, down 1% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $5.59 billion</a>.&nbsp;
Non-GAAP core revenue was flat compared to the expectations of a decline by a low-single-digit percentage year-over-year&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43298036/danaher-q4-eps-miss-expectations-amid-diagnostics-segment-lag" rel="noreferrer noopener">in the first quarter</a>.
Danaher reported second-quarter adjusted EPS of $1.88,&nbsp;down from $1.92 a year ago,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44921061/danaher-beats-q1-expectations-signals-caution-ahead-in-unusual-times" rel="noreferrer noopener">beating the consensus of $1.64</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44938778/danaher-pricing-strategy-key-to-navigating-tariff-challenges-analyst" rel="noreferrer noopener">Danaher Pricing Strategy Key To Navigating Tariff Challenges: Analyst</a>
Stifel on Tuesday wrote, &#8220;DHR&#8217;s start to the year was solid, as the company posted a beat and gave positive commentary around arguably the two most trending topics: bioprocess – where the upside case has started to materialize, and tariff impacts – which appear manageable in that they can be largely offset.&#8221;
Analyst Daniel Arias says customer demand looks strong for CDMOs and big pharma. China and smaller biotech firms are still behind, even though there&#8217;s some talk of stabilization. Overall, Stifel still sees a solid case for bioprocessing growth in 2025, possibly reaching double-digit levels.
The analyst maintains the Buy rating with a <a target="_blank" href="https://www.benzinga.com/quote/DHR/analyst-ratings" rel="noreferrer noopener">price target of $260</a>.
DHR&#8217;s stock valuation &#8220;has been a challenge for us,&#8221; the analyst wrote. Shares have sported a meaningful premium despite key businesses not having rebounded from &#8220;the 2023/2024 slowdown in biopharma.&#8221;
Stifel says management's guidance for 2025 disappointed many investors, which has brought valuation to a more approachable level.
&#8220;We believe estimates can move higher both in 2025 and 2026,&#8221; Arias said. 
The analysts see an opportunity to own DHR ahead of sentiment and end market improvement, which can yield upside for the stock.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44954335/old-dominion-earnings-shine-despite-revenue-slide" target="_blank" rel="noreferrer noopener">Old Dominion Earnings Shine Despite Revenue Slide, CEO Blames &#8216;Ongoing Softness&#8217; In Economy</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Large Cap

Guidance

Health Care

Price Target

Analyst Ratings

General

Analyst Sees Opportunity In Danaher Stock As Sentiment Improves

RBC Capital analyst Conor McNamara reiterates Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and maintains $250 price target.

Reiteration

RBC Capital Reiterates Outperform on Danaher, Maintains $250 Price Target

Goldman Sachs analyst Matthew Sykes maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $260 to $240.

Goldman Sachs Maintains Buy on Danaher, Lowers Price Target to $240

Guggenheim analyst Subbu Nambi reiterates Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and maintains $250 price target.

Guggenheim Reiterates Buy on Danaher, Maintains $250 Price Target

UBS analyst Dan Leonard maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $275 to $240.

UBS Maintains Buy on Danaher, Lowers Price Target to $240

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) underwent analysis by 12 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $244.58, a high estimate of $277.00, and a low estimate of $205.00. This current average represents a 7.48% decrease from the previous average price target of $264.36. 
<img src="https://www.benzinga.com/files/images/story/2025/1745413218_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Danaher. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Catherine Schulte &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $225.00&#x7C;$231.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $215.00&#x7C;$205.00 &#x7C; 
&#x7C;Tycho Peterson &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $260.00&#x7C;$280.00 &#x7C; 
&#x7C;Tycho Peterson &#x7C;Jefferies &#x7C;Lowers &#x7C;Buy &#x7C; $230.00&#x7C;$260.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $205.00&#x7C;$240.00 &#x7C; 
&#x7C;Daniel Arias &#x7C;Stifel &#x7C;Announces &#x7C;Buy &#x7C; $260.00&#x7C;- &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $265.00&#x7C;$285.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $277.00&#x7C;$299.00 &#x7C; 
&#x7C;Catherine Schulte &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $258.00&#x7C;$268.00 &#x7C; 
&#x7C;Brandon Couillard &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $240.00&#x7C;$280.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $240.00&#x7C;$275.00 &#x7C; 
&#x7C;Tycho Peterson &#x7C;Jefferies &#x7C;Lowers &#x7C;Buy &#x7C; $260.00&#x7C;$285.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Danaher. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Danaher compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Danaher's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Danaher's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DHR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Danaher analyst ratings.</a>
<h2>All You Need to Know About Danaher</h2>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
<h3>Danaher's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Danaher's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.08% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Danaher's net margin excels beyond industry benchmarks, reaching 16.61%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Danaher's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.15% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Danaher's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.37%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.35.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 12 Analyst Ratings Have To Say About Danaher

Baird analyst Catherine Schulte maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $231 to $225.

Baird Maintains Outperform on Danaher, Lowers Price Target to $225

Danaher Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) on Tuesday reported first-quarter 2025 sales of $5.74 billion, down 1% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $5.59 billion</a>.&nbsp;
Non-GAAP core revenue was flat compared to the expectations of a decline by a low-single-digit percentage year-over-year&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43298036/danaher-q4-eps-miss-expectations-amid-diagnostics-segment-lag" rel="noreferrer noopener">in the first quarter</a>.
Danaher reported second-quarter adjusted EPS of $1.88,&nbsp;down from $1.92 a year ago,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44921061/danaher-beats-q1-expectations-signals-caution-ahead-in-unusual-times" rel="noreferrer noopener">beating the consensus of $1.64</a>.
For FY2025, Danaher initiated adjusted EPS guidance of $7.60 to $7.75 vs. the consensus of$7.68. The company said, &#8220;We wanted to make sure everyone had an anchor point and believe having an adjusted EPS guide provides more clarity.&#8221;
Goldman Sachs writes, &#8220;DHR posted a solid quarter with Bioprocessing above expectations showing sequential order growth and book-to-bill above 1x in line with our view that Bioprocessing remains one of the more attractive areas of exposure for Tools investors. As expected, they posted a solid beat in respiratory, which should help offset some of the China IVD headwinds.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44929366/quest-diagnostics-revenue-rebound-strategic-moves-fuel-outlook-confidence" rel="noreferrer noopener">Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence</a>
&#8220;Also, they believe they can mitigate their own tariff impact through manufacturing flexibility and pricing, providing some comfort to investors for the sector as we start earnings season,&#8221; analyst Matthew Sykes writes.
Goldman Sachs maintains the Buy rating on Danaher, <a target="_blank" href="https://www.benzinga.com/quote/DHR/analyst-ratings" rel="noreferrer noopener">with a price target of $260</a>.
Goldman Sachs expects most Tools companies this quarter to beat their first-quarter earnings but stick to their full-year guidance, essentially taking the win without raising expectations.
William Blair writes, &#8220;Despite the uncertain macro backdrop, Danaher delivered a solid first-quarter print including a healthy top-line beat driven by outperformance in bioprocessing.&#8221;
Analyst Matt Larew writes that first-quarter earnings align with what we expected based on our earlier checks. These checks showed that the bioprocessing market is steadily recovering. Analyst Larew believes the company&#8217;s decision to keep its core guidance unchanged—and even slightly raise its bioprocessing growth outlook—should be seen as a positive sign, especially given the current economic conditions.
William Blair maintains the Outperform rating.
Price Action: DHR stock is up 4.32% at $192.98 at the last check Tuesday.
Read next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44928719/verizons-subscriber-losses-raise-concerns-but-strong-business-revenue-guidance-keeps-analyst-optimistic" target="_blank" rel="noreferrer noopener">Verizon&#8217;s Subscriber Losses Raise Concerns, But Strong Business Revenue, Guidance Keeps Analyst Optimistic</a></li>
</ul>
Images: Shutterstock

Danaher Pricing Strategy Key To Navigating Tariff Challenges: Analyst

JP Morgan analyst Tycho Peterson maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Overweight and lowers the price target from $280 to $260.

JP Morgan Maintains Overweight on Danaher, Lowers Price Target to $260

Jefferies analyst Tycho Peterson maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $260 to $230.

Jefferies Maintains Buy on Danaher, Lowers Price Target to $230

After Monday&#8217;s broad-based sell-off — triggered by renewed pressure from President Donald Trump on Federal Reserve Chairman Jerome Powell, raising concerns over the integrity of central bank independence — Wall Street bounced back with strength on Tuesday, buoyed by upbeat signals from <a href="https://www.benzinga.com/earnings">the corporate earnings season.</a>
By midday in New York, major indices were up by nearly 3%, with all 11 sectors of the S&amp;P 500 trading in positive territory. Consumer discretionary stocks led the rally.
The Dow Jones Industrial Average surged over 1,000 points, breaking above the 39,200 mark, as bullish momentum swept across Wall Street. Only a few S&amp;P 500 stocks remained in negative territory.
At a JPMorgan-hosted event in Washington, U.S. Treasury Secretary Scott Bessent hinted at a potential de-escalation in tensions with China, further supporting risk sentiment.
Shares of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) surged nearly 5% as investors looked ahead to the company's first-quarter earnings report, due after the closing bell.
In the bond market, after two sessions of rising Treasury yields, a modest pullback suggested some investors saw an opportunity to buy as long-dated yields neared the 5% threshold.
On the commodities front, gold briefly touched $3,500 per ounce overnight before retreating to $3,420 amid an improvement in equity market sentiment. Oil jumped 2.3%, with WTI crude reaching $64 per barrel, while copper gained 2.8%.
The cryptocurrency market also reflected a broader risk-on mood. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rallied 4% to $91,000, while Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) advanced more than 7% to $1,700.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
<td>1-day %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,321.10</td>
<td>+512.80</td>
<td>2.9%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,215.87</td>
<td>+1,045.46</td>
<td>2.7%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,297.34</td>
<td>+139.14</td>
<td>2.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,889.24</td>
<td>+48.92</td>
<td>2.7%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:10 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rallied 2.7% to $527.95.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 3.9% to $392.14.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 3% to $446.20.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 2.7% to $187.68.</li>
<li>The&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 3.8%. </li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
Stocks reacting to quarterly earnings included: 
<ul>
<li>General Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) up 4.8%</li>
<li>Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) up 0.5%,</li>
<li>RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) down 8.7%</li>
<li>Danaher Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) up 6.6%, </li>
<li>Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) up 2.4%, </li>
<li>Moody&#8217;s Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) up 3%</li>
<li>3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) up 8%</li>
<li>Northrop Grumman Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) down 13%</li>
<li>Equifax Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) up 14%. </li>
<li>Halliburton Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) down 4.9%. </li>
</ul>
Shares of First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) soared 12% as the U.S. administration imposed tariffs up to 3,521% on solar imports from Southeast Asia. 
<h1 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Gainers</h1>
<figure class="wp-block-table"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equifax Inc. </td>
<td>14.34%</td>
</tr>
<tr>
<td>First Solar, Inc. </td>
<td>12.35%</td>
</tr>
<tr>
<td>Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>)</td>
<td>9.59%</td>
</tr>
<tr>
<td>Invesco Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>)</td>
<td>9.17%</td>
</tr>
<tr>
<td>PulteGroup, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>)</td>
<td>8.30%</td>
</tr>
</tbody>
</table>
</figure>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44926902/imf-slashes-us-growth-outlook-as-trump-tariffs-bite-raises-recession-odds-to-40">IMF Slashes US Growth Outlook As Trump Tariffs Bite, Raises Recession Odds To 40%</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Government

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Federal Reserve

ETFs

$BTC

$ETH

SPDR Dow Jones Industrial Average ETF Trust

FSLR

TSLA

Select Sector SPDR-Consumer Discretionary

Wall Street Rebounds Ahead Of Tesla Earnings, Dow Adds 1,000 Points, Bitcoin Hits $91,000: What's Driving Markets Tuesday?

U.S. stocks were higher, with the Dow Jones index gaining around 600 points on Tuesday.
Shares of Quest Diagnostics Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) rose sharply during Tuesday's session following <a href="https://www.benzinga.com/quote/DGX/earnings">better-than-expected first-quarter earnings.</a>
Quest Diagnostics reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.15 per share. The company reported quarterly sales of $2.65 billion which beat the analyst consensus estimate of $2.63 billion.
Quest Diagnostics shares jumped 7.3% to $173.60 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>PureCycle Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) gained 15% to $6.39. PureCycle announced the sale of approximately $30 million in revenue bonds.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares jumped 15% to $13.36. Hesai introduced Infinity Eye, which will be available in three tailored versions A, B, and C. Each one caters to different levels of autonomous driving from basic assisted features to full automation.</li>
<li>NovaGold Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NG#NYSE">NG</a>) gained 14.7% to $3.5697 after the company and Paulson Advisers agreed to acquire Barrick&#8217;s 50% stake in Donlin Gold, forming a new partnership to develop the project.</li>
<li>Cipher Mining Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) surged 14.5% to $2.68.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) gained 13.7% to $139.15 after the US finalized plans to impose tariffs on most solar cells imported from Southeast Asia.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) jumped 13.6% to $13.74. SolarEdge Technologies will report financial results for the first quarter, before market open on Tuesday, May 6.</li>
<li>Webull Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) shares rose 13.5% to $27.97.</li>
<li>Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) jumped 13.1% to $37.59 after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates. Additionally, the company announced an authorized increase to its stock repurchase program.</li>
<li>Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) jumped 12.2% to $8.52.</li>
<li>Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) gained 11.1% to $6.99.</li>
<li>Equifax Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) gained 11% to $238.84 after the company reported better-than-expected first-quarter financial results. The company also authorized a $3 billion buyback and raised is dividend.</li>
<li>Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) gained 10.5% to $8.27.</li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) gained 8.8% to $1.22.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) rose 8.8% to $213.04.</li>
<li>Pentair plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) climbed 7.3% to $84.70 after the company reported first-quarter financial results and beat its adjusted EPS and revenue estimates.</li>
<li>3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) shares gained 6.8% to $134.63 after the company reported better-than-expected first-quarter financial results.</li>
<li>Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) rose 5.8% to $195.64 after the company reported better-than-expected first-quarter EPS and revenue.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44922024/how-to-earn-500-a-month-from-philip-morris-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Philip Morris Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Movers

BTDR

BULL

CALX

CIFR

CVNA

HSAI

MCRB

RIOT

SEDG

Quest Diagnostics Posts Better-Than-Expected Earnings, Joins Pentair, 3M, Danaher And Other Big Stocks Moving Higher On Tuesday

Danaher Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) on Tuesday reported first-quarter 2025 sales of $5.74 billion, down 1% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $5.59 billion</a>.&nbsp;
Non-GAAP core revenue was flat compared to the expectations of a decline by a low-single-digit percentage year-over-year <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43298036/danaher-q4-eps-miss-expectations-amid-diagnostics-segment-lag" rel="noreferrer noopener">in the first quarter</a>.
Danaher reported second-quarter adjusted EPS of $1.88,&nbsp;down from $1.92 a year ago, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44917043/danaher-reports-first-quarter-2025-results" rel="noreferrer noopener">beating the consensus of $1.64</a>.
Operating cash flow was $1.3 billion, and non-GAAP&nbsp;free cash flow was $1.1 billion.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/25/02/43945075/dan-loeb-adjusts-healthcare-holdings-danaher-stake-trimmed-as-thermo-fisher-gains-favor" rel="noreferrer noopener">Dan Loeb Adjusts Healthcare Holdings: Danaher Stake Trimmed As Thermo Fisher Gains Favor</a>
Rainer Blair, president and chief executive officer, stated, &#8220;Revenue, earnings, and cash flow exceeded our expectations in the first quarter–highlighted by continued momentum in bioprocessing and better-than-expected respiratory demand in our molecular diagnostics business.&#8221;
&#8220;While the macro backdrop has become more dynamic since the start of the year, it&#8217;s in times like these that Danaher&#8217;s positioning and capabilities truly stand out. We believe that the combination of our team&#8217;s DBS-driven execution, resilient portfolio and strong balance sheet will continue to differentiate Danaher in 2025 and beyond,&#8221; Blair added.
Biotechnology&nbsp;<a target="_blank" href="https://investors.danaher.com/image/Q1+2025+Danaher+Earnings+Presentation.pdf" rel="noreferrer noopener">sales</a>&nbsp;increased to $1.61 billion compared to $1.52 billion a year ago.
Sales in the Life Sciences segment fell from $1.75 billion to $1.68 billion, and diagnostic sales decreased marginally from $2.53 billion to $2.45 billion.
The adjusted operating margin reached 29.6%, down from 30.1% a year ago, surpassing the management estimate of around 26.5%.
Guidance:&nbsp;Danaher&nbsp;<a target="_blank" href="https://investors.danaher.com/image/Q1+2025+Earnings+Supplement.pdf" rel="noreferrer noopener">reaffirms</a>&nbsp;that in fiscal year 2025, non-GAAP core revenue will grow by approximately 3% year over year.
For FY2025, Danaher initiated adjusted EPS guidance of $7.60 to $7.75 vs. the consensus of$7.68. The company said, &#8220;We wanted to make sure everyone had an anchor point and believe having an adjusted EPS guide provides more clarity.&#8221;
&#8220;We are in unusual times and think it&#8217;s best to be as transparent as possible,&#8221; the company added.
The company forecasts that 2025 bioprocessing core revenue will increase in the high single digits, compared to the prior expectation of +6% to +7%.
Cepheid 2025 respiratory revenues will be around&nbsp;$1.7 billion.
For the second quarter of 2025, Danaher anticipates core revenue growth in low-single digits year over year.
The company expects an adjusted operating profit margin of ~25.5% due to a sequential decline compared to Q1. This is primarily due to lower respiratory volume at Cepheid, one of the higher-margin businesses, and the operating leverage is meaningful.
Bioprocessing core revenue growth is expected to be 7% for Q2 2025 and fiscal year 2025.
Life Sciences core revenue is expected to decline in the low-single to mid-single digits in Q2 2025 and remain flat for the fiscal year 2025.
Diagnostics sales are expected to increase in the low single digits in Q2 2025 and remain flat to low single digits in fiscal year 2025.
Price Action:&nbsp;At last check on Tuesday, DHR stock was trading 4.08% higher at $192.50 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44910307/liberty-energys-momentum-carries-into-q2-as-jpmorgan-tracks-growing-supply-side-risks" target="_blank" rel="noreferrer noopener">Liberty Energy&#8217;s Momentum Carries Into Q2 As JPMorgan Tracks Growing Supply-Side Risks</a></li>
</ul>
Photo: Shutterstock

Danaher Beats Q1 Expectations, Signals Caution Ahead In 'Unusual Times'

WIIM

Danaher shares are trading higher after the company reported better-than-expected Q1 EPS and revenue.

For FY2025, Danaher Initiates Adjusted EPS Guidance Of $7.60 To $7.75 Vs. Consensus Of $7.68, Reaffirms That Non-GAAP Core Revenue Will Grow Approximately 3% Year-Over-Year

For Q2 2025, Danaher Anticipates That Non-GAAP Core Revenue Will Grow Low-Single Digits Year-Over-Year

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) reported quarterly earnings of $1.88 per share which beat the analyst consensus estimate of $1.64 by 14.63 percent. This is a 2.08 percent decrease over earnings of $1.92 per share from the same period last year. The company reported quarterly sales of $5.74 billion which beat the analyst consensus estimate of $5.59 billion by 2.71 percent. This is a 0.95 percent decrease over sales of $5.80 billion the same period last year.

Danaher Q1 2025 Adj EPS $1.88 Beats $1.64 Estimate, Sales $5.74B Beat $5.59B Estimate

Press Releases

Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications

Compass Minerals Announces Senior Leadership Team Appointments

Danaher Reports Fourth Quarter and Full Year 2024 Results

TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

Dividends

Danaher Increases Quarterly Dividend

Danaher Announces Appointment of Charles Lamanna to Danaher Board

Danaher to Present at TD Cowen Health Care Conference

Beckman Coulter Announces FDA clearance of DxC 500i Clinical Analyzer, an integrated Clinical Chemistry and Immunoassay System

Danaher Schedules First Quarter 2025 Earnings Conference Call

Danaher Reports First Quarter 2025 Results

MRVI

MSFT

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Danaher

ニュース

パートナーシップ

ベンジンガ・グローバル